MTOR and breast carcinoma: The increasing number of PI3K/AKT/mTOR inhibitors that are currently under development for breast cancer and other malignancies suggest the potential value of PIK3CA genotyping as a tool for guiding personalized therapies, although its clinical significance still remains incompletely understood32.